An overview of the main tumor-infiltrating immune cells identified by mass cytometry showed a higher proportion of CD8+ T cells in the PD-L1 treated group (24.1%) compared to the control group (16.1%) 8 days after first injection (Fig. 1D). This evidence concerns the gene CD8A and neoplasm.